Description
Frontmatter — List of first-mentioned contributors — Contents — Introduction / Meyer, H. — I. New aspects in diabetes mellitus — The epidemiology of diabetes mellitus and its relationship with cardiovascular disease / Zimmet, P. / Serjeantson, S. — Syndrome X: fact or fiction? / Lebovitz, H. E. — Strategies for the treatment of hyperglycemia in Syndrome X / Josse, R. G. — Treatment strategies of Syndrome X – hypertension and vascular complications / Litbell, H. — Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia / Vega, G. L. — Update on the treatment of NIDDM / Lefbvre, P. J. / Sebeen, A. J. — Hyperinsulinemia and macrovascular complications in NIDDM / Standi, E. / Janka, H. U. / Stiegler, H. / Mehnert, H. — II. Quality of life in diabetes mellitus — Diabetes and quality of life: some current issues in definition and research / Croog, S. H. — Quality of life in patients with type II diabetes mellitus / Waadt, S. / Duran, G. / Waadt, M. / Herschbach, P. / Strian, F. — Well-being in non-insulin-dependent diabetic patients (NIDDM) – a long-term follow-up / Toeller, M. — III. Studies with acarbose — Acarbose monotherapy in non-insulin-dependent diabetes mellitus – the German experience / Hanefeld, M. — Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet / Willms, B. — Clinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) – a placebo-controlled double-blind comparative study / Goto, Yuichiro / Goto, Yosbio / Nakagawa, S. / Orimo, H. / Ikeda, Y. / Sakamoto, N. / Fukui, I. / Tarui, S. / Baba, S. / Kaneko, T. / Mimura, G. — Effects of long-term administration of acarbose in patients with NIDDM – a double-blind study with placebo / Sakamoto, N. / Hotta, N. / Koh, N. / Sakakibara, F. / Haga, T. / Kobayashi, M. / Kakuta, H. / Sano, T. / Yamada, H. / Matsumae, H. / Kitazawa, S. — Effects of acarbose on blood glucose control in insulindependent diabetes mellitus / Ikeda, Y. / Tsuruoka, A. / Izumi, K. / Yoshida, M. / Nakata, Y. / Omori, Y. / Sanaka, M. / Kitagawa, T. / Miyamoto, Y. / Fujita, H. / Kondo, M. / Sato, T. / Takeda, A. / Tanae, A. / Matsuoka, K. / Murakami, K. / Yamamoto, S. — European experience in the treatment of IDDM with acarbose in combination with insulin / Raptis, S. A. — Round table discussion on open questions and future aspects — IV. Abstracts — A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone / Coniff, R. F. — A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU) / Coniff, R. F. / Innerfield, R. J. — A multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus / Pi-Sunyer, F. X. — Prospective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus / Schade, D. S. — Two multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes / Holander, P. / Coniff, R. F. — Clinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy / Wernecke, J. / Dreyer, M. / Fisch, R. / Michels, G. / Lhrs, M. / Dammann, H. G. — 6 months monotherapy of NIDDM with acarbose or glibenclamide / Spengler, M. / Hnsel, G. / Boehme, K. — Decreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose / Hobler, H. / Spengler, M. — Long-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus / Goto, Yoshio / Toyota, T. / Oikawa, S. / Maruhama, Y. / Tamura, M. / Komatsu, K. / Fujiya, H. / Abe, R. / Kikuchi, H. — Clinical efficacy and tolerability of acarbose in IDDM treatment / de la Calle, H. / Escobar, F. / Figuerola, D. / Gil, E. / Herrera-Pombo, J. L. / Jimnez, A. / de Leiva, A. / Pallardo, L. F. / Pin, F. / Soler, J. / Tebar, J. / Vzquez, V. A. — Effects of acarbose on the glycemic index of different foods / Calle, A. / Rodriguez, C. / Gil, E. — Effects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics / Rohr, G. / Schmidt, I. / Schwedes, U. / Usadel, K. H. / Norenberg, Chr. / Spengler, M. — Influence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers / Rosak, C. / Boehm, B. O. / Althoff, P. H. / Hobler, H. / Boehme, K. — Acarbose: an intestinal tract a-glucosidase inhibitor – pharmacological effects on insulin and glycemia in response to a sucrose load / Tawara, K. / Mochizuki, N. / Donkai, A. / Hikima, Y. — Assessment of efficacy and tolerability of acarbose (Glucobay) by clinical data pool / Spengler, M. / Cagatay, M. — Long-term tolerability of acarbose / Spengler, M. / Hobler, H. / Cagatay, M. — Assessment of efficacy and tolerability of acarbose in diabetic patients 5 – 16 years of age / Spengler, M. / Cagatay, M. — Effect of acarbose repeated dosing on antipyrine test in healthy volunteers / Pinquier, J. L. / Pello, J. Y. / Key, E. / De Lauture, D. / D’Athis, P. / Strauch, G. / Olive, G. / Mover, I. / Prunieras, F. — Discussion
